| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Relationships were examined between Wnt5a expression and clinicopathologic factors in 178 consecutive cases of invasive breast cancer resected in our department between January 2011 and February 2014.Wnt5a was positively expressed in 69 cases among 178 cases of invasive breast cancer. Wnt5a expression was strongly correlated with being estrogen receptor (ER)-positive. Analysis of the relationship between Wnt5a expression and malignancy in exclusively 153 cases of ER-positive breast cancer led to detection of significant correlations with lymph node metastasis, nuclear grade, and lymphatic invasion. Relapse-free survival was shorter in cases of Wnt5a-positive breast cancer compared to Wnt5a-negative breast cancer cases (P = 0.024). MCF7 cells forced to constitutively express Wnt5a showed significantly enhanced migratory capacity as compared to control cells, whereas knockdown of Wnt5a reduced the capacity. ALCAM was identified as an Wnt5a-dependent expression molecule.
|
